S&P 500   5,069.53 (-0.38%)
DOW   39,069.23 (-0.16%)
QQQ   436.55 (-0.05%)
AAPL   181.16 (-0.75%)
MSFT   407.54 (-0.68%)
META   481.74 (-0.47%)
GOOGL   137.57 (-4.44%)
AMZN   174.73 (-0.15%)
TSLA   199.40 (+3.87%)
NVDA   790.92 (+0.35%)
NIO   5.65 (+4.63%)
AMD   176.01 (-0.29%)
BABA   76.51 (+0.72%)
T   16.59 (-1.25%)
F   11.95 (-1.57%)
MU   89.46 (+4.02%)
CGC   3.47 (+3.27%)
GE   154.77 (+0.94%)
DIS   107.69 (-0.05%)
AMC   4.45 (+0.23%)
PFE   27.18 (-2.09%)
PYPL   59.33 (+0.29%)
XOM   104.25 (+0.39%)
S&P 500   5,069.53 (-0.38%)
DOW   39,069.23 (-0.16%)
QQQ   436.55 (-0.05%)
AAPL   181.16 (-0.75%)
MSFT   407.54 (-0.68%)
META   481.74 (-0.47%)
GOOGL   137.57 (-4.44%)
AMZN   174.73 (-0.15%)
TSLA   199.40 (+3.87%)
NVDA   790.92 (+0.35%)
NIO   5.65 (+4.63%)
AMD   176.01 (-0.29%)
BABA   76.51 (+0.72%)
T   16.59 (-1.25%)
F   11.95 (-1.57%)
MU   89.46 (+4.02%)
CGC   3.47 (+3.27%)
GE   154.77 (+0.94%)
DIS   107.69 (-0.05%)
AMC   4.45 (+0.23%)
PFE   27.18 (-2.09%)
PYPL   59.33 (+0.29%)
XOM   104.25 (+0.39%)
S&P 500   5,069.53 (-0.38%)
DOW   39,069.23 (-0.16%)
QQQ   436.55 (-0.05%)
AAPL   181.16 (-0.75%)
MSFT   407.54 (-0.68%)
META   481.74 (-0.47%)
GOOGL   137.57 (-4.44%)
AMZN   174.73 (-0.15%)
TSLA   199.40 (+3.87%)
NVDA   790.92 (+0.35%)
NIO   5.65 (+4.63%)
AMD   176.01 (-0.29%)
BABA   76.51 (+0.72%)
T   16.59 (-1.25%)
F   11.95 (-1.57%)
MU   89.46 (+4.02%)
CGC   3.47 (+3.27%)
GE   154.77 (+0.94%)
DIS   107.69 (-0.05%)
AMC   4.45 (+0.23%)
PFE   27.18 (-2.09%)
PYPL   59.33 (+0.29%)
XOM   104.25 (+0.39%)
S&P 500   5,069.53 (-0.38%)
DOW   39,069.23 (-0.16%)
QQQ   436.55 (-0.05%)
AAPL   181.16 (-0.75%)
MSFT   407.54 (-0.68%)
META   481.74 (-0.47%)
GOOGL   137.57 (-4.44%)
AMZN   174.73 (-0.15%)
TSLA   199.40 (+3.87%)
NVDA   790.92 (+0.35%)
NIO   5.65 (+4.63%)
AMD   176.01 (-0.29%)
BABA   76.51 (+0.72%)
T   16.59 (-1.25%)
F   11.95 (-1.57%)
MU   89.46 (+4.02%)
CGC   3.47 (+3.27%)
GE   154.77 (+0.94%)
DIS   107.69 (-0.05%)
AMC   4.45 (+0.23%)
PFE   27.18 (-2.09%)
PYPL   59.33 (+0.29%)
XOM   104.25 (+0.39%)
OTCMKTS:NWPHF

Newron Pharmaceuticals (NWPHF) Stock Price, News & Analysis

$8.52
0.00 (0.00%)
(As of 02/26/2024 ET)
Today's Range
$8.52
$8.52
50-Day Range
$5.22
$8.55
52-Week Range
$5.22
$8.55
Volume
N/A
Average Volume
1,525 shs
Market Capitalization
$152.08 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

NWPHF stock logo

About Newron Pharmaceuticals Stock (OTCMKTS:NWPHF)

Newron Pharmaceuticals S.p.A., a biopharmaceutical company, focus on the development of novel therapies for the treatment of central nervous system (CNS) and pain in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson's in the European Union, Switzerland, the United Kingdom, the United States of America, Australia, Canada, Latin America, Israel, the United Arab Emirates, Japan, and South Korea. The company's product pipeline includes Evenamide, an add-on therapy for the treatment of Schizophrenia and treatment-resistant schizophrenia which is in Phase III clinical trial; and Ralfinamide for the treatment of rare neuropathic pain indication. In addition, it has a strategic partnership with Zambon for the commercialization of safinamide; and license agreement with Meiji Seika Pharma Co., Ltd., for research, develop, manufacture, and marketing of safinamide. The company was founded in 1999 and is headquartered in Bresso, Italy.

NWPHF Stock Price History

NWPHF Stock News Headlines

This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Newron Pharmaceuticals SpA NWRN
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
EQS-News: Newron appoints Margarita Chavez as board advisor
Newron Appoints Margarita Chavez as Board Advisor
EQS-News: Newron announces H1 2023 results and provides R&D update
EQS-News: Newron announces Senior Management Team changes
Newron announces Senior Management Team changes
Newron announces AGM 2023 results
EQS-News: Newron announces AGM 2023 results
Newron Pharmaceuticals S.p.A.
See More Headlines
Receive NWPHF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Newron Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
2/26/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
OTCMKTS:NWPHF
CIK
N/A
Employees
23
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$6.82 million
Book Value
$0.21 per share

Miscellaneous

Free Float
N/A
Market Cap
$152.08 million
Optionable
Not Optionable
Beta
0.53
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Mr. Stefan Weber (Age 59)
    CEO & Executive Director
    Comp: $461.48k
  • Mr. Roberto Galli
    Vice President of Finance
  • Mr. Filippo Moriggia
    Vice President of Operations
  • Dr. Ravi Anand (Age 67)
    Chief Medical Officer
    Comp: $1.09M














NWPHF Stock Analysis - Frequently Asked Questions

How have NWPHF shares performed in 2024?

Newron Pharmaceuticals' stock was trading at $5.22 at the beginning of 2024. Since then, NWPHF stock has increased by 63.2% and is now trading at $8.52.
View the best growth stocks for 2024 here
.

How do I buy shares of Newron Pharmaceuticals?

Shares of NWPHF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:NWPHF) was last updated on 2/26/2024 by MarketBeat.com Staff